Navigation Links
Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
Date:8/6/2008

LOS ANGELES, Aug. 6 /PRNewswire/ -- Vista Partners announced today that it has updated coverage and has issued a $3.57 price target on Inovio Biomedical Corporation (Amex: INO). "The proposed merger of Inovio and VGX would create a comprehensive DNA company that can create and deliver therapeutic agents and positions Inovio/VGX, based on further development progress, to move toward the same valuation arena as other gene therapy companies," said Ross Silver, Director of Research for Vista Partners. For more information and to download the free report, please visit the Vista Partners website at http://www.vistap.com and click on the "download research" icon.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Inovio Biomedical Corporation:

Inovio Biomedical (Amex: INO) is focused on developing multiple DNA-based immunotherapies. Inovio is a leader in developing human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Interim human data has shown that Inovio's DNA delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Immunotherapy partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at http://www.inovio.com.

Contact:

Vista Partners LLC

Sherry Watkins

(310)744-5268

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
3. Synvista Therapeutics to Present at the BIO InvestorForum 2007
4. Synvista Therapeutics to be Featured on Wallst.net
5. Provista Awards Agreement to Spheris
6. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
9. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
10. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
11. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... Tunnell ... for over 50 years. One of the biggest challenges faced by life sciences, biotech ... regulatory affairs services team is Kati Abraham , who is well known in ...
(Date:6/16/2017)... ... June 16, 2017 , ... Cognition Corporation , a ... more sessions of its “From the Helm” Webinar Series. , The next ... templates for design control exercises. Led by David Cronin, Cognition’s CEO, the half-hour ...
(Date:6/16/2017)... ... ... CTNext , Connecticut’s go-to resource for entrepreneurial support, today announced the ... Piers in Stamford. , Nine finalists, all of whom are Connecticut-based companies and entrepreneurs, ... secure $10,000 awards to help support business growth. The winners included:, ...
(Date:6/15/2017)... ... June 15, 2017 , ... Cybrexa ... Series B round of financing in the amount of $6 million. An investment ... participated in the round. , The Series B funding will enable Cybrexa to ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):